Exosome-Based CNS Delivery for Gene Therapy

Overview

Exosomes are small extracellular vesicles (30-150 nm) naturally secreted by most cell types, carrying protein, lipid, and nucleic acid cargo. They represent the body's own intercellular communication system and have evolved to efficiently deliver payloads between cells — including across biological barriers like the [blood-brain barrier](/entities/blood-brain-barrier) (BBB). For [neurodevelopmental epilepsies](/therapeutics/aav-gene-therapy-neurodevelopmental-epilepsy) (NDEs), exosome-based delivery offers a biologics approach that combines favorable safety properties with inherent CNS tropism[@herrmann2022].

Unlike lipid nanoparticles (LNPs), which are synthetically assembled, exosomes are biological particles with native membrane proteins and lipid compositions that can facilitate cell-type-specific targeting. This makes them attractive for delivering gene therapies to specific neuronal populations — particularly the GABAergic interneurons that are the primary therapeutic target in [Dravet syndrome](/diseases/dravet-syndrome) (via [SCN1A](/genes/scn1a)).

Biology of Exosomes

Biogenesis and Composition

Exosomes are generated through the endosomal pathway:

Overview

Exosomes are small extracellular vesicles (30-150 nm) naturally secreted by most cell types, carrying protein, lipid, and nucleic acid cargo. They represent the body's own intercellular communication system and have evolved to efficiently deliver payloads between cells — including across biological barriers like the [blood-brain barrier](/entities/blood-brain-barrier) (BBB). For [neurodevelopmental epilepsies](/therapeutics/aav-gene-therapy-neurodevelopmental-epilepsy) (NDEs), exosome-based delivery offers a biologics approach that combines favorable safety properties with inherent CNS tropism[@herrmann2022].

Unlike lipid nanoparticles (LNPs), which are synthetically assembled, exosomes are biological particles with native membrane proteins and lipid compositions that can facilitate cell-type-specific targeting. This makes them attractive for delivering gene therapies to specific neuronal populations — particularly the GABAergic interneurons that are the primary therapeutic target in [Dravet syndrome](/diseases/dravet-syndrome) (via [SCN1A](/genes/scn1a)).

Biology of Exosomes

Biogenesis and Composition

Exosomes are generated through the endosomal pathway:

Key exosome components:

• Membrane: Lipid bilayer derived from the plasma membrane, enriched in cholesterol, sphingolipids, and ceramides
• Surface proteins: Tetraspanins (CD9, CD63, CD81), integrins, MHC molecules — enabling cell-type targeting
• Interior cargo: mRNA, miRNA, siRNA, proteins, CRISPR-Cas9 components, lipids

Natural CNS Tropism

Several cell-derived exosomes exhibit natural tropism for the brain:

• Mesenchymal stromal cell (MSC) exosomes: Cross the BBB via unknown mechanisms, have shown broad CNS distribution in animal models
• Neuron-derived exosomes: Contain neural-specific cargo and surface proteins that may enable re-targeting
• Retrovirus-derived VLPs: Engineered viral-like particles combining viral fusogenicity with exosome features

Advantages for NDE Gene Therapy

| Advantage | Description | NDE Relevance |
|-----------|-------------|----------------|
| BBB crossing | Natural transcytosis capability, especially MSC-derived | Critical for systemically administered NDE therapies |
| Cell-type specificity | Surface engineering can target specific neuronal subtypes | Enable targeting of GABAergic interneurons for SCN1A |
| Immunogenicity | Low pre-existing immunity, even with repeat dosing | Safe for pediatric NDE applications |
| Cargo versatility | Carries mRNA, ASO, siRNA, CRISPR, proteins | Versatile across NDE therapeutic modalities |
| Biologic safety | No viral genes, non-replicating, biodegradable | Safer than AAV for pediatric CNS delivery |
| Neuronal uptake | Naturally fusogenic with neuronal membranes | Efficient delivery to target neurons |

Engineering Strategies

Surface Modification

Exosome surface proteins can be engineered to enhance targeting:

• CD63-displayed peptides: For enhanced BBB penetration
• Lamp2b chimeras: Fusion with targeting moieties
• Anti-Transferrin Receptor (TfR) nanobodies: Enable RMT across BBB

Cargo Loading

| Method | Description | Efficiency |
|--------|-------------|------------|
| Electroporation | Electric field pulses create pores in exosome membrane | Good for nucleic acids, may damage membranes |
| Sonication | Acoustic cavitation temporarily permeabilizes membrane | Moderate efficiency |
| Extrusion | Force cargo through exosome membrane | Higher efficiency, may damage exosome |
| Lipid fusion | Fuse liposomes loaded with cargo to exosomes | Preserves integrity |
| Endogenous loading | Engineer donor cells to load cargo into exosomes | Most physiological |
| Click chemistry | Covalent attachment of cargo to exosome surface | Enables precise targeting |

Cell-Type Targeting for NDEs

For SCN1A/Dravet therapy, exosomes must preferentially target GABAergic interneurons:

• Engineered exosomes displaying GABAergic-specific surface markers (e.g., parvalbumin-targeting peptides)
• Exosomes derived from GABAergic neuron cultures
• Dual-targeting strategies: BBB-crossing + neuronal subtype targeting

Clinical Applications in NDEs

Exosome-Encapsulated ASOs

For [Angelman syndrome](/diseases/angelman-syndrome) and UBE3A-targeting therapies, exosome delivery of GTX-102 or similar ASOs could improve CNS penetration and reduce off-target peripheral effects[@mohammad2023].

Potential advantages over naked ASO delivery:

• 10-50x higher brain exposure in animal models
• Reduced peripheral organ accumulation (liver, kidney)
• Extended duration of CNS residence

Exosome-mRNA for Dravet

Exosome-encapsulated SCN1A mRNA could provide transient expression of functional Nav1.1 channels in inhibitory interneurons, potentially bridging the gap before developmental damage becomes irreversible.

CRISPR-Cas9 Delivery

Exosomes can deliver CRISPR-Cas9 systems (mRNA + gRNA) for gene editing in CNS neurons. This is particularly relevant for:

• SCN1A gene correction: Direct fixing of pathogenic variants
• UBE3A activation: Epigenetic editing approaches
• KCNQ2/CDKL5 correction: Engineering functional gene variants[@strempfl2024]

Manufacturing and Scale-Up

Challenges

Industrial Approaches

| Company/Group | Approach | Status |
|---------------|----------|--------|
| Caperna (Roche) | Engineered exosomes for CNS delivery | Preclinical |
| Evox Therapeutics | Engineered exosome platform | Preclinical |
| Codiak BioSciences | exoSTING and exoIL-12 programs | Clinical (oncology) |
| PureTech | Glyph technology (exosome targeting) | Research |
| Academic consortia | MSC exosome GMP production | GMP-grade available |

GMP Manufacturing

Clinical-grade exosome manufacturing follows a standardized pathway:

Current GMP exosome costs are high (~$10,000-50,000 per patient dose) but expected to decrease with improved manufacturing efficiency.

Comparison to Other Delivery Platforms

| Factor | Exosomes | LNP | AAV |
|--------|----------|-----|-----|
| BBB penetration | Moderate-high (engineered) | Low-moderate | Moderate |
| Cell-type specificity | High (surface engineering) | Moderate | Serotype-dependent |
| Immunogenicity | Very low | Low | Moderate-high |
| Manufacturing scale | Challenging | Scalable | Complex |
| Cargo capacity | Large (proteins, mRNA, CRISPR) | Large (mRNA, CRISPR) | Limited (~4.7kb) |
| Duration | Transient | Transient | Long-term |
| Redosing | Fully repeatable | Fully repeatable | Limited |
| Cost | High | Moderate | Very high |
| Clinical stage | Early (mostly preclinical) | Growing (CNS trials) | Mature (multiple approved) |

Key Open Questions

Cross-Links

• [Lipid Nanoparticle CNS Delivery](/technologies/lipid-nanoparticle-cns-delivery) — competing non-viral platform](/technologies)
• [AAV Vectors](/technologies/aav-vectors) — viral delivery counterpart](/technologies)
• [Gene Therapy for Neurodevelopmental Epilepsy](/technologies/gene-therapy-neurodevelopmental-epilepsy) — hub page](/technologies)
• [Focused Ultrasound Neuromodulation](/technologies/focused-ultrasound-neuromodulation) — BBB opening for enhanced delivery](/technologies)
• [SCN1A Gene](/genes/scn1a) — Dravet syndrome target](/genes)
• [UBE3A Gene](/genes/ube3a) — Angelman syndrome target](/genes)
• [Dravet Syndrome Foundation](/organizations/dravet-syndrome-foundation) — patient advocacy organization](/organizations)
• [Angelman Syndrome Foundation](/organizations/angelman-syndrome-foundation) — patient advocacy organization